Alberto Guijosa
Panamericana, DIF, Mexico
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Non-traditional barriers to participation in pharmacologic chronic kidney disease clinical trials.
Journal: BMC nephrology
Published: June 30, 2025
Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 18, 2025
Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country.
Journal: JCO global oncology
Published: December 05, 2024
Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097-6110.
Journal: Current oncology (Toronto, Ont.)
Published: October 14, 2024
Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score.
Journal: Oncology
Published: August 12, 2024
Representation of Low- and Middle-Income Countries in CKD Drug Trials: A Systematic Review.
Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation
Published: March 01, 2024
Validation and implementation of TaqMAMA RT-PCR for SARS-CoV-2 variant surveillance: experience from a high-volume setting.
Journal: BMC infectious diseases
Published: October 26, 2023
Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer.
Journal: Current oncology (Toronto, Ont.)
Published: May 18, 2023
Examining the Role of Histaminergic, Orexinergic, and Cannabinergic Systems in Redox Regulation in Gastric Adenocarcinoma.
Journal: Mini reviews in medicinal chemistry
Published: September 06, 2022
Last Updated: 09/26/2026